Actavis receives subpoena from DoJ regarding marketing and pricing of generics
The Actavis unit of Allergan (NYSE: AGN) has received a subpoena from the US Department of Justice regarding information on the marketing and pricing of certain generic drugs.
The subpoena also sought information about communications with competitors regarding their products. The US Department of Health and Human Services (HHS) said earlier this year that it will investigate price increases for generic medicines in the USA. This will include plans to review quarterly prices for the top 200 generic drugs from 2005 to 2014.
Analysis by Centers for Medicare and Medicaid, which underpinned the investigation into pricing of generics, found that nearly 10% of generic drugs more than doubled in price in a recent year, while half of generic medicines went up in price between July 2, 2013, to June 30, 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze